PL-09 side effects of anti-angiogenic drugs

Thrombosis Research

Volumn 129, Issue SUPPL. 1, 2012, Pages

  Elice, Francesca ^a   Rodeghiero, Francesco ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Anti angiogenic drugs; Cancer; Cancer treatment; Hemostasis; Thrombosis

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PACLITAXEL; PLACEBO; SORAFENIB; SUNITINIB; WARFARIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANTIANGIOGENIC THERAPY; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COLON CANCER; COLORECTAL CANCER; CONFERENCE PAPER; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HEMATEMESIS; HEMOPTYSIS; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; THROMBOSIS; THROMBOSIS PREVENTION; VAGINA BLEEDING; ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY);

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; HEMORRHAGE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862154963     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(12)70016-6     Document Type: Conference Paper

References (37)

1. HP Gerber, N Ferrara Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res 165 3 2005 671 680 (Pubitemid 40216420)
2. D Keefe, J Bowen, R Gibson, T Tan, M Okera, A Stringer Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review Oncologist 16 4 2011 432 444
3. HS Rugo, RS Herbst, G Liu, JW Park, MS Kies, HM Steinfeldt et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results J Clin Oncol 23 24 2005 5474 5483
4. E Fox, R Aplenc, R Bagatell, MK Chuk, E Dombi, W Goodspeed et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors J Clin Oncol 28 35 2010 5174 5181
5. BE Houk, CL Bello, B Poland, LS Rosen, GD Demetri, RJ Motzer Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis Cancer Chemother Pharmacol 66 2 2010 357 371
6. O Rixe, RM Bukowski, MD Michaelson, G Wilding, GR Hudes, O Bolte et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 11 2007 975 984 (Pubitemid 47629888)
7. FF Kabbinavar, J Hambleton, RD Mass Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 2005 3706 3712
8. B Escudier, T Eisen, WM Stadler, C Szczylik, S Oudard, M Siebels et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2 2007 125 134 (Pubitemid 46089673)
9. DH Johnson, L Fehrenbacher, WF Novotny et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191 (Pubitemid 41095154)
10. Roche: Avastin Summary of Product Characteristics. 2005.
11. A Sandler, R Gray, MC Perry et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
12. RA Somer, E Sherman, CJ Langer Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599 Clin Lung Cancer 9 2 2008 102 105 (Pubitemid 351631921)
13. AB Sandler, JH Schiller, R Gray, I Dimery, J Brahmer, M Samant et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab J Clin Oncol 27 9 2009 1405 1412
14. RJ Motzer, TE Hutson, P Tomczak, MD Michaelson, RM Bukowski, O Rixe, S Oudard, S Negrier, C Szczylik, ST Kim, I Chen, PW Bycott, CM Baum, RA Figlin Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2 2007 115 124 (Pubitemid 46089672)
15. MA Socinski, S Novello, JR Brahmer, R Rosell, JM Sanchez, CP Belani et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small cell lung cancer J Clin Oncol 26 4 2008 650 656 (Pubitemid 351264362)
16. EP Rock, V Goodman, JX Jiang, K Mahjoob, SL Verbois, D Morse et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma Oncologist 12 1 2007 107 113 (Pubitemid 46143508)
17. B Escudier, T Eisen, WM Stadler, C Szczylik, S Oudard, M Siebels TARGET Study Group Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2 2007 125 134 (Pubitemid 46089673)
18. MJ Ratain, T Eisen, WM Stadler, KT Flaherty, SB Kaye, GL Rosner et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 16 2006 2505 2512 (Pubitemid 46630627)
19. LL Siu, A Awada, CH Takimoto, M Piccart, B Schwartz, T Giannaris et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer Clin Cancer Res 12 1 2006 144 151 (Pubitemid 43166188)
20. Y Je, FA Schutz, TK Choueiri Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials Lancet Oncol 10 10 2009 967 974
21. S Kilickap, H Abali, I Celik Bevacizumab, bleeding, thrombosis, and warfarin J Clin Oncol 21 18 2003 3542 author reply, 3543.
22. BC Kuenen Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors Pathophysiol Haemost Thromb 33 1 2003 13 14 (Pubitemid 37490520)
23. JM Roodhart, MH Langenberg, E Witteveen, EE Voest The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway Curr Clin Pharmacol 3 2 2008 132 143
24. T Meyer, L Robles-Carrillo, T Robson, F Langer, H Desai, M Davila et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice J Thromb Haemost 7 1 2009 171 181
25. F Elice, F Rodeghiero, A Falanga, FR Rickles Thrombosis associated with angiogenesis inhibitors Best Pract Res Clin Haematol 22 1 2009 115 128
26. FA Scappaticci, JR Skillings, SN Holden, HP Gerber, K Miller, F Kabbinavar et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 16 2007 1232 1239 (Pubitemid 47299901)
27. J Hambleton, WF Novotny, H Hurwitz, L Fehrenbacher, T Cartwright, J Hainsworth et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation J Clin Oncol 2 Suppl 2004 abstract 3528.
28. J Hambleton, J Skillings, F Kabbinavar, E Bergsland, E Holmgren, SN Holden et al. Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC) J Clin Oncol 23 suppl 2005 259s (abstract 3554).
29. F Kabbinavar, HI Hurwitz, L Fehrenbacher Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 1 2003 60 65
30. BJ Giantonio, DE Levy, PJ O'dwyer, NJ Meropol, PJ Catalano, AB Benson 3rd, Eastern Cooperative Oncology Group A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200 Ann Oncol 17 9 2006 1399 1403 (Pubitemid 44400378)
31. BJ Giantonio, PJ Catalano, NJ Meropol, PJ O'Dwyer, EP Mitchell, SR Alberts et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 12 2007 1539 1544 (Pubitemid 46733080)
32. HS Hochster, LL Hart, RK Ramanathan, BH Childs, JD Hainsworth, AL Cohn et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study J Clin Oncol 26 21 2008 3523 3529
33. CJ Allegra, G Yothers, MJ O'Connell, S Sharif, LH Colangelo, SH Lopa et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer J Clin Oncol 27 20 2009 3385 3390
34. KD Miller, LI Chap, FA Holmes et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 2005 792 799 (Pubitemid 46224178)
35. MH Cohen, J Gootenberg, P Keegan, R Pazdur FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer Oncologist 12 6 2007 713 718 (Pubitemid 47036205)
36. GD Demetri, AT van Oosterom, CR Garrett, ME Blackstein, MH Shah, J Verweij et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 9544 2006 1329 1338 (Pubitemid 44528723)
37. GK Abou-Alfa, L Schwartz, S Ricci, D Amadori, A Santoro, A Figer et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma J Clin Oncol 24 26 2006 4293 4300 (Pubitemid 46630787)